JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

JNJ

174.13

+0.25%↑

ABBV

198.84

-0.12%↓

AZN

74.32

+0.36%↑

NVS

118.56

+0.28%↑

ABT

130.85

-2.14%↓

Search

Omeros Corp

Ouvert

SecteurSoins de santé

4.09 2

Résumé

Variation du prix de l'action

24h

Actuel

Min

3.95

Max

4.18

Chiffres clés

By Trading Economics

Revenu

-2.1M

-33M

Ventes

412K

412K

Marge bénéficiaire

-8,121.359

Employés

202

EBITDA

-1.9M

-35M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+117.39% upside

Dividendes

By Dow Jones

Prochains Résultats

13 août 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-173M

249M

Ouverture précédente

2.09

Clôture précédente

4.09

Sentiment de l'Actualité

By Acuity

26%

74%

57 / 374 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

Omeros Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 août 2025, 17:49 UTC

Principaux Mouvements du Marché

180 Life Sciences Stock Jumps on $156 Million Notes Sale

11 août 2025, 17:18 UTC

Principaux Mouvements du Marché

Tiziana Life Sciences Rises After FDA Approves IND for Foralumab Trial

11 août 2025, 16:25 UTC

Résultats

Correction to Constellation Software 2Q Revenue Rises, Profit Shrinks Article on Aug. 8

11 août 2025, 23:50 UTC

Market Talk

Nikkei May Rise as Yen Weakens -- Market Talk

11 août 2025, 23:42 UTC

Market Talk

Global Energy Roundup: Market Talk

11 août 2025, 23:42 UTC

Market Talk

Woodside's Share Price Implies Lofty Oil Price -- Market Talk

11 août 2025, 23:36 UTC

Market Talk

Gold Edges Higher on Likely Technical Recovery -- Market Talk

11 août 2025, 23:32 UTC

Market Talk

Argosy's New Bull Sees Sentiment Toward REITs Improving -- Market Talk

11 août 2025, 23:02 UTC

Market Talk

RBA Set to Lower OCR With New Forecasts in Focus -- Market Talk

11 août 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

11 août 2025, 20:37 UTC

Résultats
Acquisitions, Fusions, Rachats

Bakkt Holdings: Andy Main Will Step Dn as Co-CEO and Director, Effective Aug 11, and Akshay Naheta Will Assume Role of CEO >BKKT

11 août 2025, 20:37 UTC

Résultats
Acquisitions, Fusions, Rachats

Bakkt Holdings 2Q Rev $577.9M >BKKT

11 août 2025, 20:37 UTC

Résultats
Acquisitions, Fusions, Rachats

Bakkt Holdings: In Upcoming Qtr, Will Conduct Comprehensive Review of Cost Structure to Ensure We Are Optimized, Driving Synergies Across Business, and Accelerating Path to Profitability >BKKT

11 août 2025, 20:22 UTC

Résultats

Exodus Movement: Assets 2,058 Units of Bitcoin Valued at $220.5M, 2,729 Units of Ether Valued at $6.8M, $58.1M in Cash and Cash Equivalents, USD Coin, Treasury Bills as of June 30 >EXOD

11 août 2025, 20:22 UTC

Résultats

Exodus Movement: Monthly Active Users 1.5M at End 2Q, Unchanged From 1.5M as of June 30, 2024 >EXOD

11 août 2025, 20:22 UTC

Résultats

Exodus Movement: Processed Volume $1.38B in 2Q Dn 37% From 1Q, Bitcoin, Tether (TRX Network), Tether (ETH Network), USDC, SOL Top Assets Traded in 2Q >EXOD

11 août 2025, 20:22 UTC

Résultats

Exodus Movement: Digital Assets and Liquid Assets $291.2M >EXOD

11 août 2025, 20:22 UTC

Résultats

Exodus Movement 2Q Rev $25.8M >EXOD

11 août 2025, 20:14 UTC

Market Talk

Canada Dollar Faces Near-Term Weakness on Trade Row, September Rate-Cut Chatter -- Market Talk

11 août 2025, 19:12 UTC

Market Talk

Crude-Oil Futures Edge Up in Rangebound Trade -- Market Talk

11 août 2025, 18:56 UTC

Market Talk

U.S. Natural-Gas Futures Fall on Forecast Loss of Late August Heat -- Market Talk

11 août 2025, 18:31 UTC

Market Talk

Mining Halt Could Lift Lithium Prices in Near Term -- Market Talk

11 août 2025, 17:43 UTC

Market Talk

Freeport-McMoRan Can Push Up Prices, Profits With Copper Tariff Protection -- Market Talk

11 août 2025, 17:28 UTC

Market Talk

Crossborder Trade Tensions Accelerate Softness in Canada Rents -- Market Talk

11 août 2025, 17:16 UTC

Market Talk

Commodity Longs Fall to 11-Month Low -- Market Talk

11 août 2025, 16:42 UTC

Acquisitions, Fusions, Rachats

Adobe Stock Gets a Downgrade. 'AI Is Eating Software,' Analyst Says. -- Barrons.com

11 août 2025, 16:27 UTC

Acquisitions, Fusions, Rachats

BBVA Says Sabadell Offer Remains in Effect

11 août 2025, 16:26 UTC

Acquisitions, Fusions, Rachats

BBVA Previously Said It Won't Withdraw Offer to Buy Sabadell

11 août 2025, 16:25 UTC

Acquisitions, Fusions, Rachats

Banco de Sabadell Announced TSB Sale on July 1

11 août 2025, 16:25 UTC

Acquisitions, Fusions, Rachats

Banco de Sabadell Shareholders Approved TSB Unit Sale on Aug 6

Comparaison

Variation de prix

Omeros Corp prévision

Objectif de Prix

By TipRanks

117.39% hausse

Prévisions sur 12 Mois

Moyen 9 USD  117.39%

Haut 9 USD

Bas 9 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

1

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

6.265 / 7.49Support & Résistance

Court Terme

Very Strong Bearish Evidence

Moyen Terme

Bearish Evidence

Long Terme

Weak Bullish Evidence

Sentiment

By Acuity

57 / 374Classement par Soins de santé

Sentiment de l'Actualité

Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Omeros Corp

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.